CVAC Stock Analysis: Buy, Sell, or Hold?
CVAC - CureVac N.V. Ordinary Shares
$4.66
-0.01 (-0.21%)
▼
5d:
+8.37%
30d:
-9.95%
90d:
-14.5%
BUY
MODERATE Confidence
Analysis Updated: Jan 5, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When CVAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CVAC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CVAC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CVAC is currently trading at $4.66, which is considered fair based on recent price action.
Technical Outlook: Technically, CVAC is in a strong downtrend. The price is approaching resistance at $4.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CVAC scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.38 (+15.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CVAC is in a strong downtrend. The price is approaching resistance at $4.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CVAC scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.38 (+15.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
54/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
78.9%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Trading below Wall St target ($5.38)
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
Support & Resistance Levels
Support Level
$4.00
Resistance Level
$4.68
Current Trend
Strong Downtrend
Technical data as of
Jan 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.38
Wall Street Target
$5.38
(+15.6%)
Revenue Growth (YoY)
-89.0%
Earnings Growth (YoY)
24.0%
Profit Margin
182.1%
Share & Embed Analysis
Last updated: August 23, 2026 11:24 PM ET
Data refreshes hourly during market hours. Next update: 12:24 AM
Data refreshes hourly during market hours. Next update: 12:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
